David Nierengarten

David Nierengarten Analyst Performance

Managing Director, Equity Research at Wedbush

David Nierengarten is a stock analyst at Wedbush in the healthcare sector, covering 56 publicly traded companies. Over the past year, David Nierengarten has issued 127 stock ratings, including buy and hold recommendations. While full access to David Nierengarten's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Nierengarten's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
335 Last 11 Years
Buy Recommendations
76.67% 253 Buy Ratings
Companies Covered
56 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.9%3 ratings
Buy75.8%250 ratings
Hold22.7%75 ratings
Sell0.6%2 ratings

Out of 330 total stock ratings issued by David Nierengarten at Wedbush, the majority (75.8%) have been Buy recommendations, followed by 22.7% Hold, 0.9% Strong Buy, and 0.6% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
92.9% of companies on NASDAQ
52 companies
NYSEAMERICAN
1.8% of companies on NYSEAMERICAN
1 company
OTCMKTS
1.8% of companies on OTCMKTS
1 company
NYSE
1.8% of companies on NYSE
1 company
TSE
1.8% of companies on TSE
1 company

David Nierengarten, an analyst at Wedbush, currently covers 56 companies listed on NASDAQ, NYSEAMERICAN, OTCMKTS, NYSE and TSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
56 companies
100.0%

David Nierengarten of Wedbush specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
48 companies
85.7%
PHARMACEUTICALS
7 companies
12.5%
HEALTHCARE EQUIPMENT & SUPPLIES
1 company
1.8%

About David Nierengarten

David Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy. His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models. In addition, David has results in predicting Dendreon’s looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor. David received his B.S. in Biochemistry from the University of Wisconsin-Madison, and Ph.D. in Molecular and Cell Biology from the University of California at Berkeley.

David Nierengarten's Ratings History at Wedbush

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
11/17/2026Reiterated Rating$7.79Outperform
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
11/11/2026Lower Price Target$2.29$9.00Outperform
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
11/11/2026Boost Price Target$25.65$33.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
11/10/2026Reiterated Rating$0.86$7.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
11/10/2026Lower Price Target$12.56$19.00Neutral
Telix Pharmaceuticals Limited stock logo
TLPPF
Telix Pharmaceuticals
11/4/2026Reiterated Rating$8.95$22.00Outperform
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
11/4/2026Boost Price Target$27.46$30.00Outperform
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
11/4/2026Lower Price Target$96.63$120.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
10/29/2026Lower Price Target$9.55$24.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
10/28/2026Boost Price Target$88.80$102.00Outperform
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
10/28/2026Lower Price Target$26.24$28.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
10/27/2026Reiterated Rating$17.89$35.00Outperform
Xencor, Inc. stock logo
XNCR
Xencor
10/27/2026Boost Price Target$29.18$45.00Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
10/27/2026Lower Price Target$9.07$14.00Outperform
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
10/27/2026Downgrade$4.17$4.00Neutral
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
10/21/2026Reiterated Rating$11.16$22.00Outperform
Xencor, Inc. stock logo
XNCR
Xencor
10/21/2026Reiterated Rating$24.94$30.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
10/21/2026Lower Price Target$92.59$96.00Neutral
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
10/19/2026Boost Price Target$76.17$110.00Outperform
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
10/15/2026Reiterated Rating$10.52$60.00Outperform
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
10/14/2026Reiterated Rating$24.43$65.00Outperform
argenex SE stock logo
ARGX
argenex
10/8/2026Lower Price Target$818.25$1,130.00Outperform
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
10/2/2026Boost Price Target$6.84$14.00Outperform
Aktis Oncology stock logo
AKTS
Aktis Oncology
10/2/2026Reiterated Rating$18.38$35.00Outperform
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
9/29/2026Reiterated Rating$20.75$40.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
9/23/2026Reiterated Rating$11.95$22.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
9/22/2026Lower Price Target$103.45$118.00Neutral
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
9/16/2026Reiterated Rating$5.80$11.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
9/16/2026Reiterated Rating$32.74$55.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
9/15/2026Reiterated Rating$47.39$64.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
9/15/2026Reiterated Rating$2.77$11.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
9/14/2026Reiterated Rating$55.41$64.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
9/14/2026Reiterated Rating$11.29$22.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
9/10/2026Reiterated Rating$76.51$100.00Outperform
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
9/9/2026Reiterated Rating$8.86$25.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
9/9/2026Boost Price Target$12.74$13.00Neutral
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
9/9/2026Reiterated Rating$90.79$123.00Outperform
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
9/9/2026Reiterated Rating$26.83$65.00Outperform
argenex SE stock logo
ARGX
argenex
9/3/2026Reiterated Rating$1,055.37$1,150.00Outperform
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
9/2/2026Downgrade$0.42$1.00Neutral
A Bill Would Reprice America's Gold at Market Value (Ad)

The US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.tc pixel

Request your free 2026 Gold Guide to see what repricing could mean for you.
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
9/2/2026Boost Price Target$78.67$100.00Outperform
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
8/26/2026Lower Price Target$107.36$123.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
8/21/2026Reiterated Rating$56.41$64.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
8/20/2026Reiterated Rating$12.30$22.00Outperform
Aktis Oncology stock logo
AKTS
Aktis Oncology
8/19/2026Initiated Coverage$25.00$35.00Outperform
argenex SE stock logo
ARGX
argenex
8/18/2026Boost Price Target$987.84$1,150.00Outperform
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
8/13/2026Reiterated Rating$21.30$60.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
8/12/2026Boost Price Target$26.05$35.00Outperform
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
8/12/2026Boost Price Target$51.04$64.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
8/12/2026Boost Price Target$23.76$33.00Outperform
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
8/12/2026Boost Price Target$12.19$16.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
8/10/2026Reiterated Rating$51.45$58.00Outperform
Xencor, Inc. stock logo
XNCR
Xencor
8/6/2026Boost Price Target$19.10$30.00Outperform
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
8/5/2026Boost Price Target$103.85$130.00Outperform
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
7/30/2026Boost Price Target$28.99$40.00Outperform
Xencor, Inc. stock logo
XNCR
Xencor
7/30/2026Reiterated Rating$19.86$26.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
7/29/2026Boost Price Target$79.83$99.00Outperform
argenex SE stock logo
ARGX
argenex
7/28/2026Boost Price Target$888.82$1,050.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
7/24/2026Boost Price Target$19.99$20.00Neutral
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
7/23/2026Reiterated Rating$6.51$11.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
7/21/2026Reiterated Rating$22.22$31.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
7/21/2026Reiterated Rating$50.78$58.00Outperform
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
7/13/2026Reiterated Rating$38.03$55.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
7/10/2026Boost Price Target$15.44$17.00Neutral
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
7/6/2026Reiterated Rating$11.87$22.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6/30/2026Boost Price Target$96.15$110.00Neutral
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
6/29/2026Boost Price Target$59.96$72.00Outperform
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
6/23/2026Reiterated Rating$0.87$5.00Outperform
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
6/22/2026Downgrade$132.61$135.00Neutral
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
6/16/2026Reiterated Rating$81.95$100.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
6/15/2026Reiterated Rating$13.39$12.00Neutral
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
6/12/2026Reiterated Rating$21.51$35.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
6/12/2026Reiterated Rating$18.76$31.00Outperform
argenex SE stock logo
ARGX
argenex
6/11/2026Reiterated Rating$882.46$1,000.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
6/10/2026Reiterated Rating$69.99$88.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
6/9/2026Downgrade$122.87$124.00Neutral
argenex SE stock logo
ARGX
argenex
6/4/2026Reiterated Rating$813.14$1,000.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6/2/2026Upgrade$129.69$90.00Neutral
ODTX
Odyssey Therapeutics
6/2/2026Initiated Coverage$16.96$30.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
5/29/2026Reiterated Rating$35.21$55.00Outperform
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
5/28/2026Initiated Coverage$25.21$35.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
5/28/2026Reiterated Rating$107.38$125.00Outperform
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
5/27/2026Boost Price Target$84.60$135.00Outperform
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
5/26/2026Initiated Coverage$25.89$42.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
5/12/2026Reiterated Rating$14.42$12.00Neutral
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
5/8/2026Boost Price Target$6.48$11.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
5/5/2026Reiterated Rating$4.66$11.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
5/5/2026Reiterated Rating$3.78$11.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
4/29/2026Boost Price Target$54.04$59.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
4/20/2026Reiterated Rating$4.20$11.00Outperform
Your Social Security check is scheduled for a 22% cut (Ad)

The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel

Download the free Debt Death Spiral report now
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
4/16/2026Boost Price Target$46.31$58.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
4/16/2026Reiterated Rating$12.24$18.00Neutral
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
4/16/2026Reiterated Rating$4.83$11.00Outperform
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
4/16/2026Reiterated Rating$6.50$13.00Outperform
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
4/13/2026Boost Price Target$64.47$80.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
4/13/2026Reiterated Rating$10.54$22.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4/8/2026Reiterated Rating$102.25$125.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
4/7/2026Reiterated Rating$9.09$22.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
4/2/2026Reiterated Rating$4.50$11.00Outperform
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
4/1/2026Boost Price Target$49.16$58.00Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
4/1/2026Lower Price Target$12.67$17.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3/31/2026Reiterated Rating$19.52$30.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
3/27/2026Reiterated Rating$4.41$11.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3/18/2026Reiterated Rating$4.95$11.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
3/17/2026Reiterated Rating$35.68$55.00Outperform
argenex SE stock logo
ARGX
argenex
3/9/2026Reiterated Rating$717.80$1,000.00Outperform
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
3/6/2026Boost Price Target$5.10$8.00Outperform
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3/5/2026Boost Price Target$1.08$5.00Outperform
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
3/3/2026Boost Price Target$67.77$95.00Outperform
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2/25/2026Boost Price Target$32.29$65.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
2/25/2026Boost Price Target$43.50$53.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2/24/2026Initiated Coverage$132.91$110.00Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
2/24/2026Reiterated Rating$11.71$20.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2/17/2026Lower Price Target$55.99$88.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
2/10/2026Reiterated Rating$5.69$11.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
1/30/2026Reiterated Rating$4.01$11.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
1/21/2026Reiterated Rating$39.90$55.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
1/15/2026Reiterated Rating$72.74Outperform
Immunome, Inc. stock logo
IMNM
Immunome
1/15/2026Reiterated Rating$20.76$31.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
1/15/2026Reiterated Rating$13.77$18.00Neutral
argenex SE stock logo
ARGX
argenex
1/14/2026Reiterated Rating$810.51$1,000.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
1/13/2026Reiterated Rating$17.43$30.00Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
1/13/2026Reiterated Rating$9.15$20.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
1/13/2026Boost Price Target$41.12$50.00Outperform
Generation Bio Co. stock logo
GBIO
Generation Bio
12/16/2025Set Price Target$5.39$5.50Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
12/8/2025Reiterated Rating$11.00$20.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
12/2/2025Reiterated Rating$40.07$48.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
11/17/2025Reiterated Rating$108.00$125.00Outperform
argenex SE stock logo
ARGX
argenex
11/14/2025Boost Price Target$894.31$1,000.00Outperform
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
11/10/2025Reiterated Rating$33.21$50.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
11/7/2025Lower Price Target$9.84$7.00Neutral
Xencor, Inc. stock logo
XNCR
Xencor
11/6/2025Reiterated Rating$14.24$26.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
10/30/2025Set Price Target$12.37$9.00
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
10/28/2025Reiterated Rating$40.45$48.00Outperform
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
10/27/2025Upgrade$1.65$7.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
10/17/2025Boost Price Target$74.36$110.00Outperform
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10/15/2025Boost Price Target$31.85$70.00Outperform
argenex SE stock logo
ARGX
argenex
10/13/2025Boost Price Target$796.92$880.00Outperform
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
10/13/2025Boost Price Target$37.89$44.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
10/13/2025Reiterated Rating$3.73$6.00Outperform
Beyond NVDA: The World’s Next #1 Company? (Ad)

This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.tc pixel

Discover the small-cap company at the center of this tech revolution.
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
9/8/2025Initiated Coverage$1.55$4.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
9/8/2025Reiterated Rating$3.88$6.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
9/8/2025Reiterated Rating$80.89$115.00Outperform
Xencor, Inc. stock logo
XNCR
Xencor
9/2/2025Reiterated Rating$8.55$26.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
8/28/2025Reiterated Rating$12.10$22.00Outperform
Generation Bio Co. stock logo
GBIO
Generation Bio
8/13/2025Downgrade$4.05$7.00Neutral
Xencor, Inc. stock logo
XNCR
Xencor
8/7/2025Lower Price Target$7.49$26.00Outperform
ImageneBio, Inc. stock logo
IMA
ImageneBio
7/25/2025Lower Price Target$16.32$23.00Neutral
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
6/26/2025Reiterated Rating$0.84Outperform
argenex SE stock logo
ARGX
argenex
6/24/2025Reiterated Rating$550.14$715.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
6/23/2025Reiterated Rating$3.53$11.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
6/12/2025Reiterated Rating$17.92$22.00Outperform
argenex SE stock logo
ARGX
argenex
6/11/2025Reiterated Rating$575.46$715.00Outperform
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
6/11/2025Reiterated Rating$2.14$5.00Outperform
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
6/5/2025Initiated Coverage$17.48$22.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
5/23/2025Reiterated Rating$8.66$30.00Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
5/19/2025Reiterated Rating$9.09$10.00Neutral
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
5/15/2025Reiterated Rating$2.24$5.00Outperform
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
5/8/2025Reiterated Rating$3.12$8.00Neutral
NovoCure Limited stock logo
NVCR
NovoCure
4/16/2025Lower Price Target$15.66$27.00Neutral
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
4/16/2025Reiterated Rating$20.59$34.00Outperform
argenex SE stock logo
ARGX
argenex
4/11/2025Reiterated Rating$577.38$715.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3/27/2025Reiterated Rating$13.21$31.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3/26/2025Reiterated Rating$2.27$11.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
3/20/2025Reiterated Rating$8.64$33.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3/17/2025Reiterated Rating$2.60$11.00Outperform
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3/14/2025Downgrade$12.50$20.00Neutral
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
3/6/2025Reiterated Rating$0.91$5.00Neutral
Chimerix, Inc. stock logo
CMRX
Chimerix
3/5/2025Reiterated Rating$8.43$8.55Neutral
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
2/12/2025Reiterated Rating$13.09$31.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
2/6/2025Initiated Coverage$12.72$31.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
2/5/2025Upgrade$12.60Strong-Buy
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2/3/2025Reiterated Rating$17.27$40.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
1/24/2025Reiterated Rating$4.01$11.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
1/13/2025Reiterated Rating$27.38$29.00Neutral
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
1/13/2025Reiterated Rating$3.40$11.00Outperform
NovoCure Limited stock logo
NVCR
NovoCure
12/2/2024Reiterated Rating$29.85$29.00Neutral
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
11/21/2024Reiterated Rating$3.01$11.00Outperform